Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?

American Journal of Obstetrics and Gynecology

Volumn 204, Issue 1, 2011, Pages 19.e1-19.e6

  Greene, Mark H ^a   Mai, Phuong L ^a   Schwartz, Peter E ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bilateral oophorectomy; bilateral salpingectomy; BRCA1 2 mutation carrier; ovarian cancer risk; risk reducing surgery

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; HIGH RISK POPULATION; HUMAN; MUTATION; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; RISK MANAGEMENT; SALPINGOOOPHORECTOMY; SURGICAL RISK; THEORY;

EID: 78650690262     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.05.038     Document Type: Article

References (44)

1. N.M. Lindor, M.L. McMaster, C.J. Lindor, and M.H. Greene Concise handbook of familial cancer susceptibility syndromes, second ed J Natl Cancer Inst Monogr 2008 1 93
2. T.R. Rebbeck, N.D. Kauff, and S.M. Domchek Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers J Natl Cancer Inst 101 2009 80 87
3. T.R. Rebbeck, T. Friebel, and T. Wagner Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group J Clin Oncol 23 2005 7804 7810
4. A. Eisen, J. Lubinski, and J. Gronwald Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers J Natl Cancer Inst 100 2008 1361 1367
5. S.S. Tworoger, K.M. Fairfield, G.A. Colditz, B.A. Rosner, and S.E. Hankinson Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk Am J Epidemiol 166 2007 894 901
6. A.C. Antoniou, M. Rookus, and N. Andrieu Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort study Cancer Epidemiol Biomarkers Prev 18 2009 601 610
7. S.A. Narod, P. Sun, and P. Ghadirian Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study Lancet 357 2001 1467 1470
8. J.R. McLaughlin, H.A. Risch, and J. Lubinski Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study Lancet Oncol 8 2007 26 34
9. S. Kelekci, B. Yilmaz, L. Yasar, K. Savan, S. Sonmez, and C. Kart Ovarian reserve and ovarian stromal blood supply after tubal ligation by the Pomeroy technique: comparison with controls Gynecol Endocrinol 20 2005 279 283
10. I. Kutlar, A. Ozkur, O. Balat, M.G. Ugur, Y. Genco, and F. Aksoy Effects of three different sterilization methods on utero-ovarian Doppler blood flow and serum levels of ovarian hormones Eur J Obstet Gynecol Reprod Biol 122 2005 112 117
11. S. Kelekci, B. Yilmaz, Y. Yakut, L. Yasar, K. Savan, and S. Sonmez Hormonal and ovarian stromal blood supply changes after laparoscopic tubal sterilization: a prospective controlled study Contraception 73 2006 279 283
12. J.E. Muscat, and M.S. Huncharek Perineal talc use and ovarian cancer: a critical review Eur J Cancer Prev 17 2008 139 146
13. M.A. Gates, S.S. Tworoger, and K.L. Terry Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer Cancer Epidemiol Biomarkers Prev 17 2008 2436 2444
14. C.B. Powell, E. Kenley, and L.-M. Chen Risk-reducing salpingo- oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy J Clin Oncol 23 2005 127 132
15. J.W. Carlson, A. Miron, and E.A. Jarboe Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention J Clin Oncol 26 2008 4160 4165
16. S.N. Agoff, J.E. Mendelin, V.S. Grieco, and R.L. Garcia Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up Am J Surg Pathol 26 2002 171 178
17. M.L. Carcangiu, B. Peissel, B. Pasini, G. Spatti, P. Radice, and S. Manoukian Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature Am J Surg Pathol 30 2006 1222 1230
18. T.J. Colgan, J. Murphy, D.E.C. Cole, S. Narod, and B. Rosen Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status Am J Surg Pathol 25 2001 1283 1289
19. A. Finch, P. Shaw, B. Rosen, J. Murphy, S.A. Narod, and T.J. Colgan Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers Gynecol Oncol 100 2006 58 64
20. K. Leeper, R. Garcia, E. Swisher, B. Goff, B. Greer, and P. Paley Pathologic findings in prophylactic oophorectomy specimens in high-risk women Gynecol Oncol 87 2002 52 56
21. K.H. Lu, J.E. Garber, and D.W. Cramer Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy J Clin Oncol 18 2000 2728 2732
22. F. Medeiros, M.G. Muto, and Y. Lee The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome Am J Surg Pathol 30 2006 230 236
23. A.K. Folkins, E.A. Jarboe, and A. Saleemuddin A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations Gynecol Oncol 109 2008 168 173
24. J.M. Piek, P. Kenemans, and R.H. Verheijen Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause Am J Obstet Gynecol 191 2004 718 732
25. J.M. Piek, R.H. Verheijen, and F.H. Menko Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition Histopathology 43 2003 26 32
26. J.M.J. Piek, P.Jv. Diest, and R.P. Zweemer Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer J Pathol 195 2001 451 456
27. R. Drapkin, C.P. Crum, and J.L. Hecht Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia Hum Pathol 35 2004 1014 1021
28. D.W. Kindelberger, Y. Lee, and A. Miron Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship Am J Surg Pathol 31 2007 161 169
29. A.K. Folkins, E.A. Jarboe, M.H. Roh, and C.P. Crum Precursors to pelvic serous carcinoma and their clinical implications Gynecol Oncol 113 2009 391 396
30. R.I. Olivier, M. van Beurden, and M.A.C. Lubsen Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up Br J Cancer 90 2004 1492 1497
31. M.J. Callahan, C.P. Crum, and F. Medeiros Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction J Clin Oncol 25 2007 3985 3990
32. B.B.J. Hermsen, P.J.V. Diest, and J. Berkhof Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer Int J Cancer 119 2006 1412 1418
33. F. Laki, Y.M. Kirova, and P. This Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation Cancer 109 2007 1784 1790 (Pubitemid 46668541)
34. J.D. Lamb, R.L. Garcia, B.A. Goff, P.J. Paley, and E.M. Swisher Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy Am J Obstet Gynecol 194 2006 1702 1709
35. M.H. Greene, M. Piedmonte, and D. Alberts A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study Cancer Epidemiol Biomarkers Prev 17 2008 594 604
36. M.S. Beattie, B. Crawford, F. Lin, E. Vittinghoff, and J. Ziegler Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers Genet Test 13 2009 1 6
37. V. Kram, T. Peretz, and M. Sagi Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing Familial Cancer 5 2006 327 335
38. K.A. Metcalfe, D. Birenbaum-Carmeli, and J. Lubinski International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers Int J Cancer 122 2008 2017 2022
39. K.M. Schmeler, C.C. Sun, and D.C. Bodurka Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations Obstet Gynecol 108 2006 515 520
40. H.A. Risch, J.R. McLaughlin, and D.E.C. Cole Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer Am J Hum Genet 68 2001 700 710
41. S. Chen, and G. Parmigiani Meta-analysis of BRCA1 and BRCA2 penetrance J Clin Oncol 25 2007 1329 1333
42. J.L. Kramer, I.A. Velazquez, B.E. Chen, P.S. Rosenberg, J.P. Struewing, and M.H. Greene Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers J Clin Oncol 23 2005 8629 8635
43. A. Eisen, J. Lubinski, and J. Klijn Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study J Clin Oncol 23 2005 7491 7496 (Pubitemid 46291812)
44. H.B. Peterson, G. Jeng, and S.G. Folger The risk of menstrual abnormalities after tubal sterilization N Engl J Med 343 2000 1681 1687